Does Modafinil Reliably Improve Vigilance in Sleep-Deprived Pilots? What an 11-Person Crossover Study Actually Shows

Short answer: In a randomized crossover experiment involving 11 military student pilots, modafinil was associated with faster responses and fewer lapses on a computerized vigilance task during parts of an overnight wakefulness challenge. Yet the magnitude of the task advantage varied substantially among participants. The within-protocol ordering of individual reaction-time benefits was comparatively stable (reported intraclass correlation coefficient, ICC, 0.90), while the corresponding stability for self-reported sleepiness was low (0.19). Neither statistic demonstrates that a particular pilot was safe to fly, that a particular drug concentration caused the result, or that the same person would respond identically on a future operation.

The primary research is Van Cutsem and colleagues’ 2025 paper, Stable interindividual differences in modafinil’s effect on vigilance during sleep deprivation, published in Frontiers in Pharmacology. Its original full report is available at doi:10.3389/fphar.2025.1607444. The central forensic distinction is between observed computerized performance, subjective confidence or sleepiness, and an actually measured specimen concentration. These are not interchangeable forms of proof.

Why this study matters to fatigue and stimulant interpretation

Fatigue-related cases often involve an intuitive but unsupported assumption: if a wake-promoting agent reduces sleepiness, it must also restore operational judgment and eliminate safety risk. This study tests a narrower proposition. It asks whether repeated measures of psychomotor vigilance improve with modafinil during extended wakefulness, whether individual benefits remain relatively consistent across the sampled hours, and whether pilots correctly perceive their own performance. That separation is valuable even outside aviation. A person’s speed on one computerized task, self-assessment, and ability to manage real threats are different outcomes that require different evidence.

The investigators drew their participants from a highly selected military student-pilot population, rather than patients being evaluated for intoxication or the general driving public. Participants’ training and screening may help standardize this small research group, but those same characteristics limit generalizability. A good group average does not prove that each person responded beneficially; an unusually favorable individual task result does not by itself establish legal or operational fitness.

What was the genuine biological sample size?

The experiment included 11 independent student pilots, approximately 21 ± 2 years of age, including one woman. Each person participated in two intervention periods, modafinil and placebo, in randomized counterbalanced order with a 10-day washout. Because the same individuals supplied observations under both conditions, the experiment was a crossover, not a trial of 22 separate volunteers. Its many hourly vigilance measurements were repeated observations nested within those 11 people, not additional independent human participants.

Four volunteers were additionally genotyped for candidate COMT and PER3 variants. That subgroup is only four people, not 11 genetically characterized individuals, and the authors did not conduct inferential statistical genotype testing on it. Any suggestion that a DNA result could reliably select an ideal dose or identify a safe pilot would exceed this report.

Exactly what drug regimen and comparator were tested?

In the active period, participants took 200 mg of oral modafinil at 8 p.m. on the first study day and another 200 mg at 4 p.m. on the following day. Thus the planned total was 400 mg across two administrations, not one 400-mg dose and not a concentration measured in blood. In the control period, they received a calcium-lactate placebo that was described to participants as slow-release caffeine for the purposes of expectancy control. It was not a true caffeine-versus-modafinil head-to-head comparison.

Each experimental period had a three-day schedule. Participants completed familiarization activities and an approximately four-hour flight-simulation exercise before the evening administration, followed by overnight wakefulness and scheduled online testing. They could sleep or nap after the required overnight segment according to the study protocol. Consequently, results sampled the combination of drug assignment, time awake, time of day, and the later permitted recovery interval; they did not test continuous flight operations through the entire dosing period.

Where were measurements taken, and what did the laboratory actually assay?

The main measurements were computerized psychomotor vigilance task (PVT) responses and questionnaire ratings collected remotely at participants’ homes under online supervision. The PVT yielded unadjusted reaction time in milliseconds, an adjusted reaction-time metric, accuracy percentage, and a lapse count. Participants also rated sleepiness, estimated their prospective and retrospective performance, and reported symptoms. A medical officer supervised remotely; vital signs were self-recorded at designated intervals.

No participant modafinil concentration in venous whole blood, separated plasma, serum, urine, oral fluid, hair, or another toxicological specimen was chemically assayed in the reported experiment. The paper’s discussion of expected plasma peak timing and elimination draws on prior pharmacokinetic literature; it is not a set of measured samples from these 11 pilots. There is no LC-MS/MS or GC-MS result for modafinil from these sessions, and no parent-drug concentration-versus-PVT regression. A prescribed oral milligram dose is an administration record, not a forensic specimen concentration.

For the general analytical distinction among physical specimen types, the site’s published biological matrices guide explains why blood, plasma, serum, urine, and other materials answer different questions. This modafinil study does not provide data from any such drug-testing matrix.

What happened to reaction speed and vigilance lapses overnight?

The investigators reported significant condition-by-time interactions across the PVT measures. At 2 a.m. and 4 a.m., modafinil-period task performance generally exceeded the placebo-period performance in each of the four recorded PVT metrics. Reported group comparisons of the four outcomes were significant at those times, with maximum stated p values of 0.034 and 0.022, respectively. The phrase group comparison matters: it describes average paired behavior in a small cohort, not a reliable performance threshold for an individual worker.

At 4 a.m., unadjusted reaction time averaged 333 ± 41 ms under modafinil and 383 ± 75 ms under placebo. The mean lapse count was 3 ± 3 versus 12 ± 13. These are standard deviations across study participants and do not express a confidence interval for a future pilot’s response. Placebo-period PVT performance deteriorated over the extended-wakefulness interval; some slowing remained even in the active condition, so the result is a relative improvement rather than restored unfatigued baseline function.

At 2 a.m., unadjusted reaction time was 330 ± 37 ms with modafinil and 368 ± 59 ms with placebo, while recorded accuracy was 87 ± 11% versus 65 ± 31%. At 6 a.m., however, the paper did not mark the same significant between-condition difference in Table 1, despite numerical separation. Some differences reappeared at 8 a.m. and the last scheduled afternoon measurement. It would therefore be misleading to write that every metric differed significantly at every measured hour.

Original evidence table 1: selected PVT observations

Table entries are observations, not blood toxicology measurements. The published table denotes statistical contrasts by symbols, and only selected rows are transcribed here into a new interpretive layout. It is not scientifically valid to infer a new p value from the displayed rounded means and standard deviations without the paired participant-level data. The reported 1.8% missing data were imputed using time-point means, another reason not to treat the numbers as exact subject histories.

Were individual modafinil response differences stable?

The study’s most distinctive result concerns differences among people, rather than simply the average benefit. For each participant and time point, the investigators calculated a modafinil effectiveness score by subtracting active-period unadjusted PVT reaction time from placebo-period reaction time. They then estimated the proportion of variance attributable to differences between participants as opposed to variation within participants across the observed sampling times.

For this reaction-time benefit score, the reported ICC was 0.90. The variance components were 1,720 between participants and 189 within participants, consistent with a large proportion of observed variance belonging to stable relative individual differences over this particular protocol. That is suggestive of a trait-like response profile under the study conditions. But there was only one modafinil and one placebo trial per person, with multiple samples during those periods: ICC 0.90 is not evidence of a separately replicated dose challenge weeks later, not a predictive accuracy statistic, and not proof that each pilot has a fixed clinically useful responder category.

There were no serial assayed modafinil concentrations, controlled flying endpoints, or independent validation cohort to demonstrate that the reaction-time rank is a durable pharmacokinetic phenotype. The apparent consistency could be influenced by baseline PVT speed, fatigue susceptibility, circadian patterns, expectancy, home testing, missing-data treatment, and the particular schedule. A robust-sounding coefficient must remain attached to the outcome and repeated-measure structure that generated it.

Why did subjective sleepiness tell a different story?

Self-reported sleepiness also improved at the overnight circadian low points: at 2 a.m. the visual analog sleepiness score averaged 21 ± 18 with modafinil versus 37 ± 24 with placebo, and at 4 a.m. the comparison was 20 ± 10 versus 36 ± 24. The study reported p = 0.002 at 2 a.m. and p = 0.029 at 4 a.m. Nevertheless, sleepiness ratings later reversed direction: participants reported greater sleepiness in the modafinil period at later daytime follow-up measurements, with reported p = 0.018 and 0.019.

Crucially, stability in the sleepiness difference score was only ICC 0.19, with between-person variance 18 and within-person variance 77. That low value means a given person’s relative reported sleepiness benefit shifted more across the sampled hours than their relative reaction-time benefit. A favorable subjective score on one occasion therefore cannot be treated as a stable biological test of individual sensitivity to modafinil, and a high PVT-responder ranking does not automatically imply a similarly stable subjective rating.

Original evidence table 2: objective, subjective, and null findings

A nonsignificant result is not proof of equal effects, particularly with 11 participants and noisy measurements. Likewise, the absence of a measured event cannot be described as a statistically demonstrated null result. Real aerial emergency recognition, legal driving safety, and clinically confirmed adverse events were not evaluated as objective outcomes.

Could the pilots accurately judge how well they were performing?

The authors compared participants’ predictions and retrospective evaluations of PVT performance with actual unadjusted reaction time. In the placebo period, prospective performance estimates correlated weakly with task response time (r = −0.35; p < 0.001), and retrospective estimates showed a moderate association (r = −0.47; p < 0.001). The corresponding active-condition associations did not achieve statistical significance. This is a useful warning about relying on subjective confidence, although it does not diagnose overconfidence in any particular individual.

There was an overall condition effect for retrospective task evaluation (reported F(1,10) = 7.9, p = 0.018), but the data do not yield a validated personal self-monitoring accuracy threshold. Correlations calculated across repeated time points require care: many task-rating pairs do not suddenly become many independent pilots. Changes in response-time variance under active medication could also influence the apparent associations. The safest inference is that subjective awareness did not track objectively measured PVT speed in the same manner in the two treatment periods.

Did anyone actually fly while affected by modafinil?

No performance trial in an aircraft under active drug was reported. The scheduled flight-simulation exercise preceded the evening intervention; the authors did not use a later blinded airborne examination, instrument flight task, navigation-error record, or real emergency scenario to validate PVT benefit. Asking whether a volunteer felt safe to fly is not an operational certification or a demonstrated crash-avoidance outcome. Four participants reported at least one unsafe-to-fly judgment during the modafinil period, compared with seven under placebo, but the percentage-of-observations contrast did not attain conventional statistical significance (p = 0.054).

These distinctions become essential when a legal argument moves from a controlled cognitive task to actual pilot or motorist behavior. Tasks can estimate one component of attention and still miss multi-tasking, judgment, spatial orientation, stress reactions, instrument interpretation, and unexpected hazards. A forensic expert should avoid conflating apparent vigilance benefit with safe task completion in an entirely different environment.

What about side effects, vital signs, and recovery sleep?

Five participants reported one or more symptoms during modafinil administration, including headache, gastrointestinal complaints, nausea, palpitations, and nervousness; two participants reported headache in the control period. The group comparison of self-reported side-effect occurrence was not significant. Heart rate, blood pressure, body temperature, and respiratory rate were also not statistically distinguishable by the reported condition/time analyses. But these vital signs were self-recorded during remote visits rather than acquired by a blinded clinical physiology laboratory.

The sleep diary did not identify a statistically significant treatment difference in the next recovery sleep interval. That observation is restricted to self-reported time in bed, estimated total sleep, subjective quality, and related diary variables. Polysomnography was not used, so objective sleep architecture, sleep-related breathing events, and clinically important rare reactions were not excluded. The small pilot cohort cannot establish general safety of repeated operational off-label stimulant use.

Can COMT, PER3, or chronotype identify the best responder?

Only four of the 11 student pilots supplied COMT and PER3 genotype information. The study described apparent differences across those few individuals but deliberately did not perform formal genotype hypothesis tests. Two were in one COMT category and two in another; all four belonged to the same stated PER3 category. There is no valid estimate of genetic predictive value, sensitivity, specificity, or calibration from this small subset. Such a dataset cannot support genetic personnel selection or an individualized flight-safety judgment.

The authors also explored self-reported sleep quality and chronotype by dividing the tiny cohort into subgroups. Those classifications did not significantly account for the mean treatment-difference scores. An absence of significance at this scale should not be turned into a broad assertion that sleep traits or genes have no relationship with fatigue vulnerability. Nor should individual curves in Figures 6 and 7 be mined into unvalidated new cutoff rules.

What confounding and statistical limitations matter most?

First, the research was small and highly selected. Eleven people completed repeated online measures in their own homes, where individual environmental control and compliance cannot be verified to the same level as laboratory confinement. Second, blinding failed: all participants correctly identified whether they had taken modafinil rather than the nominal slow-release caffeine comparator. Expectancy can affect subjective ratings and possibly behavior. Third, only a single active/placebo crossover sequence was tested per participant, even though the ICC incorporated multiple time points.

Fourth, 1.8% of the data were missing and replaced with means at the corresponding time point. Mean imputation can reduce the apparent spread and affect covariances, especially in a small dataset. Fifth, numerous outcomes and intervals were evaluated, so the particular corrected comparisons reported by the authors must not be mixed with exploratory effects as though all were equally pre-specified. Sixth, the protocol sampled recovery time and shifted circadian context after the sustained-wakefulness phase. These features complicate any simple claim that a drug’s effect persists at a fixed magnitude for a predictable number of hours.

Finally, the raw military participant data were not publicly available for external individual-level reanalysis without authorization. An expert can accurately explain the published group pattern and its uncertainties, but cannot reconstruct one student’s true medication concentration, confirm compliance for every individual, or validate incident-specific causation from the published figures.

How should forensic toxicology distinguish dosing, testing, and performance?

A documented oral dose establishes what investigators intended to administer under supervision. It does not show absorption, distribution, elimination, or a contemporaneous concentration in a particular specimen. A PVT response time is a direct behavioral observation under defined task instructions; it is not an analytical instrument result for modafinil. A subjective sleepiness score is a self-report under study conditions; it is not identical to a lapses score. The ICC is a statistical property of the observed individual contrast trajectories, not a drug concentration, a medical diagnosis, or an impairment probability.

Where a real investigation has a quantified blood or plasma sample, its identification and assay evidence should be analyzed on their own terms, using the actual validated method and specimen timing. The published confirmatory drug testing guide discusses that separate analytical inquiry, while the therapeutic drug monitoring guide explains why even measured concentrations need context. Neither changes what was—or was not—measured in this student-pilot experiment.

What would a stronger real-world study need?

To test whether the individualized response finding predicts a later mission, investigators would need genuinely replicated dosing sessions per person, a larger representative cohort, and prospectively specified performance targets. A protocol could standardize sleep restriction, control expectancy and adherence more tightly, record actual timed medication concentrations in an identified matrix, and measure operationally relevant events with blinded evaluation. Physiological telemetry and objective sleep measurement would clarify safety and recovery better than unsupervised diary entries alone.

Even a stronger population study would still require separate evidence before judging an individual event. The dose administered, clinical history, time awake, other substances, job demands, actual performance record, and specimen chain of custody may all matter; none can be replaced with an average RT effect from 11 student pilots. The best use of this original paper is to illuminate the scientific gap between temporary task benefit and person-specific fitness.

Frequently asked questions about the modafinil pilot study

1. Did modafinil eliminate the effects of sleep deprivation?

No. Relative to placebo, several PVT outcomes improved at selected hours, but reaction times still varied with wakefulness and not every time-point comparison was significant. Restoration of baseline cognition, continuous alertness, and reliable operational flight performance were not established.

2. Were there 11 pilots or more than 100 participants because tasks were repeated?

There were 11 independent pilots, each undergoing two periods and many repeated PVT tests. The repeated task records increased observations per person but did not increase the independent biological participant count. Four of those pilots, not four additional pilots, had exploratory genotype information.

3. Does an ICC of 0.90 mean a person’s response is 90% predictable?

No. The ICC described the relative distribution of variance in reaction-time difference scores across sampled time points within this single crossover study. It was not validated as 90% individual prediction accuracy, a responder classification sensitivity, or stability across new operational deployments.

4. Why was the sleepiness ICC only 0.19?

The between-person component of the reported sleepiness benefit was small compared with the within-person component over the assessed hours. Participants’ subjective relative benefit shifted more with time than their PVT reaction-time benefit. The two ICCs concern different endpoints and should not be conflated.

5. Was modafinil measured in the pilots’ blood?

No chemical drug measurements from human whole blood, centrifuged plasma, or other forensic matrices were reported. Two 200-mg oral administrations were scheduled, but measured drug ng/mL, exposure AUC, and concentration-versus-impairment curves were absent from the study.

6. Did the study prove modafinil made these pilots safe to fly?

No. Actual flight performance under the study medication was not independently validated. Feeling unsafe to fly was self-reported, and its condition comparison was nonsignificant at p = 0.054. PVT benefit cannot be converted directly into an operational or legal safety finding.

7. Can this result determine whether a particular driver or pilot was impaired in litigation?

No. It supports a limited group-level conclusion concerning timed vigilance-task behavior and variable personal responses under a specific protocol. Individual impairment or incident causation requires the relevant person’s actual facts, verified specimens where available, observed performance, and a defensible causal analysis.

Bottom line: separate vigilance benefit from individual fitness

The study is strong enough to raise an important question and modest enough to demand careful interpretation: in 11 student pilots, modafinil was associated with better computerized vigilance during part of a sleep-deprivation challenge, while the observed relative reaction-time advantage differed by person and appeared stable across repeated within-protocol hours. Subjective sleepiness tracked a different, less stable pattern, and subjective performance awareness did not mirror the placebo relationship. No direct modafinil toxicology concentrations or real operational safety endpoints were obtained. The full primary source, rather than a headline or a generalized stimulant assumption, is the appropriate basis for a forensic reading: Van Cutsem et al., 2025, doi:10.3389/fphar.2025.1607444.